Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations

Figures

• 

  Figure 1. Local and systemic side effects reported after the first vaccine dose in the post-infected population (n = 78), and after the second vaccine dose in the naïve population (n = 177). (A) Overall side effects and symptoms in both populations (p = 0.88). (B) Relative frequency of each reported local and systemic side effects (a participant possibly having more than one symptom). Error bars represent 95% confidence intervals. Mild, does not interferes with daily activity; moderate, some interference with activity, or temperature > 38.5 °C; severe, prevents daily activity, temperature > 39 °C, or emergency department visit or hospitalization3.

• 

  Figure 2. Serological response to BNT162b2 mRNA COVID-19 vaccine in post-infected individuals and naive population. The boxplot’s central mark indicates the median, and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. p = 0.307 between the post-infected pre-vaccination group and the naïve population after the first dose, otherwise p < 0.0001.

• 

  Figure 3. Scatterplot of the time from infection to first vaccination in days, and IgG-S responses in the post-infected cohort. r is Pearson's correlation coefficient.

• 

  Figure 4. Scatterplot of the IgG-S responses before vaccination, and the corresponding responses after the first dose in the post-infected cohort (blue), and before vaccination and after the second does in the naive cohort (green). r is Pearson's correlation coefficient. The 95% prediction interval is presented in the gray area. Post-infected participants who were found seronegative prior to their vaccination are highlighted in red.